Literature DB >> 22075967

p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation.

Hideo Nakamura1, Satoaki Matoba, Eri Iwai-Kanai, Masaki Kimata, Atsushi Hoshino, Mikihiko Nakaoka, Maki Katamura, Yoshifumi Okawa, Makoto Ariyoshi, Yuichiro Mita, Koji Ikeda, Mitsuhiko Okigaki, Souichi Adachi, Hideo Tanaka, Tetsuro Takamatsu, Hiroaki Matsubara.   

Abstract

BACKGROUND: Diabetic cardiomyopathy is characterized by energetic dysregulation caused by glucotoxicity, lipotoxicity, and mitochondrial alterations. p53 and its downstream mitochondrial assembly protein, synthesis of cytochrome c oxidase 2 (SCO2), are important regulators of mitochondrial respiration, whereas the involvement in diabetic cardiomyopathy remains to be determined. METHODS AND
RESULTS: The role of p53 and SCO2 in energy metabolism was examined in both type I (streptozotocin [STZ] administration) and type II diabetic (db/db) mice. Cardiac expressions of p53 and SCO2 in 4-week STZ diabetic mice were upregulated (185% and 152% versus controls, respectively, P<0.01), with a marked decrease in cardiac performance. Mitochondrial oxygen consumption was increased (136% versus control, P<0.01) in parallel with augmentation of mitochondrial cytochrome c oxidase (complex IV) activity. Reactive oxygen species (ROS)-damaged myocytes and lipid accumulation were increased in association with membrane-localization of fatty acid translocase protein FAT/CD36. Antioxidant tempol reduced the increased expressions of p53 and SCO2 in STZ-diabetic hearts and normalized alterations in mitochondrial oxygen consumption, lipid accumulation, and cardiac dysfunction. Similar results were observed in db/db mice, whereas in p53-deficient or SCO2-deficient diabetic mice, the cardiac and metabolic abnormalities were prevented. Overexpression of SCO2 in cardiac myocytes increased mitochondrial ROS and fatty acid accumulation, whereas knockdown of SCO2 ameliorated them.
CONCLUSIONS: Myocardial p53/SCO2 signal is activated by diabetes-mediated ROS generation to increase mitochondrial oxygen consumption, resulting in excessive generation of mitochondria-derived ROS and lipid accumulation in association with cardiac dysfunction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075967     DOI: 10.1161/CIRCHEARTFAILURE.111.961565

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  40 in total

Review 1.  Metabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome.

Authors:  David Roul; Fabio A Recchia
Journal:  Antioxid Redox Signal       Date:  2015-04-30       Impact factor: 8.401

Review 2.  Mechanisms of lipotoxicity in the cardiovascular system.

Authors:  Adam R Wende; J David Symons; E Dale Abel
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

3.  Sodium Butyrate Protects -Against High Fat Diet-Induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice.

Authors:  Ling Zhang; Jianfeng Du; Naohiro Yano; Hao Wang; Yu Tina Zhao; Patrycja M Dubielecka; Shougang Zhuang; Y Eugene Chin; Gangjian Qin; Ting C Zhao
Journal:  J Cell Biochem       Date:  2017-04-25       Impact factor: 4.429

4.  Cardiac deficiency of single cytochrome oxidase assembly factor scox induces p53-dependent apoptosis in a Drosophila cardiomyopathy model.

Authors:  Leticia Martínez-Morentin; Lidia Martínez; Sarah Piloto; Hua Yang; Eric A Schon; Rafael Garesse; Rolf Bodmer; Karen Ocorr; Margarita Cervera; Juan J Arredondo
Journal:  Hum Mol Genet       Date:  2015-03-19       Impact factor: 6.150

Review 5.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Does p53 Inhibition Suppress Myocardial Ischemia-Reperfusion Injury?

Authors:  Toshiyuki Yano; Koki Abe; Masaya Tanno; Takayuki Miki; Atsushi Kuno; Tetsuji Miura; Charles Steenbergen
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-03-19       Impact factor: 2.457

7.  Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy.

Authors:  Rui Ni; Ting Cao; Sidong Xiong; Jian Ma; Guo-Chang Fan; James C Lacefield; Yanrong Lu; Sydney Le Tissier; Tianqing Peng
Journal:  Free Radic Biol Med       Date:  2015-11-11       Impact factor: 7.376

Review 8.  Diabetic cardiomyopathy and metabolic remodeling of the heart.

Authors:  Pavan K Battiprolu; Camila Lopez-Crisosto; Zhao V Wang; Andriy Nemchenko; Sergio Lavandero; Joseph A Hill
Journal:  Life Sci       Date:  2012-10-30       Impact factor: 5.037

Review 9.  Proteasome biology and therapeutics in cardiac diseases.

Authors:  Sanket Kumar Shukla; Khadija Rafiq
Journal:  Transl Res       Date:  2018-09-28       Impact factor: 7.012

10.  Deficiency of a lipid droplet protein, perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction.

Authors:  Kenta Kuramoto; Fumie Sakai; Nana Yoshinori; Tomoe Y Nakamura; Shigeo Wakabayashi; Tomoko Kojidani; Tokuko Haraguchi; Fumiko Hirose; Takashi Osumi
Journal:  Mol Cell Biol       Date:  2014-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.